Analyst on Ambu downgrade: Doesn't change investment case
Sydbank analyst calls the adjustment "discouraging news" for the medtech company, but highlights that the visualization business isn't affected.
BY MARKETWIRE, TRANSLATED BY DANIEL PEDERSEN
Tuesday evening's Ambu downgrade is obviously not good news, having made waves in the share price on Wednesday, but the medtech company's announcement really doesn't change its investment case, at least according to Senior Equity Analyst at Sydbank Søren Løntoft Hansen.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Ambu downgrades financial expectations
For subscribers
